Unknown

Dataset Information

0

Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results.

ABSTRACT:

SUBMITTER: Anderlini P 

PROVIDER: S-EPMC4245073 | biostudies-literature | 2012 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results.

Anderlini Paolo P   Saliba Rima M RM   Ledesma Celina C   Chancoco Christina C   Alousi Amin M AM   Shpall Elizabeth J EJ   Popat Uday R UR   Hosing Chitra M CM   Khouri Issa F IF   Nieto Yago Y   Ciurea Stefan S   Younes Anas A   Fanale Michelle A MA   Acholonu Sandra S   Valverde Rosamar R   Champlin Richard E RE  

Leukemia & lymphoma 20111024 3

Similar Datasets

Unknown Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma.
| S-EPMC5193224 | biostudies-literature
Unknown Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS.
| S-EPMC5119961 | biostudies-literature
Unknown Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual disease.
| S-EPMC11810767 | biostudies-literature
Unknown Reduced-Intensity Conditioning with Fludarabine, Melphalan, and Total Body Irradiation for Allogeneic Hematopoietic Cell Transplantation: The Effect of Increasing Melphalan Dose on Underlying Disease and Toxicity.
| S-EPMC6451676 | biostudies-literature
Unknown Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party.
| S-EPMC11893469 | biostudies-literature
Unknown Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning.
| S-EPMC9278281 | biostudies-literature
Unknown Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.
| S-EPMC5743624 | biostudies-literature
Unknown Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma.
| S-EPMC7575614 | biostudies-literature
Unknown Allogeneic stem cell transplantation combined with conditioning regimen including donor-derived CAR-T cells for refractory/relapsed B-cell lymphoma.
| S-EPMC10073016 | biostudies-literature
Unknown Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation.
| S-EPMC7319212 | biostudies-literature